As the pharmaceutical industry advances into a high-tech future, companies are leveraging cutting-edge artificial intelligence (AI) technologies to accelerate drug discovery and development.
With the pharma industry set to spend a staggering $3 billion on AI in drug discovery by 2025, pharmaceutical companies are responding by making strides to evolve with the times.
Among the transformative trends shaping the industry’s trajectory is the adoption of virtual clinical trials. This research methodology breaks away from the confines of traditional health settings, ushering in a new era of digitally-driven data collection. Participants receive pharmaceutical substances and equipment directly, empowering them to contribute to research from the comfort of their own homes.
The emergence of these trends reflects a fundamental shift toward a more efficient and patient-centric drug development paradigm. By embracing innovations like AI-driven research and virtual clinical trials, pharmaceutical companies are poised to streamline operations, enhance health outcomes and adapt to the evolving challenges of the healthcare landscape.
This edition of Pharma Tech Outlook brings insights into the latest developments in drug discovery and development and how companies align with the latest trends and services.
It features a thought leadership article by Jessica Wilson Rayse, associate director of product management at Accugenix at Charles River Laboratories, who shares her insights on the importance of contamination control strategies in pharmaceutical and consumer care manufacturing. It also features an article by Nicholas Smalley, VP of regulatory affairs at Kindeva Drug Delivery, who shares his view on navigating the regulatory landscape.
In this edition of Pharma Tech Outlook, we also bring you the story of the top drug discovery and development providers. One of them is ChemoGenics BioPharma, which offers integrated preclinical drug discovery services and collaborative research initiatives to facilitate the advancement of transformative therapies within the pharmaceutical industry.
In this edition featuring the top drug discovery and development solutions providers 2024, we hope you find the right partner to meet your organization’s needs.
